重组Anti-VLDL Receptor/VLDL-R抗体[EPR26178-72] (BSA and Azide free) (ab302918)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR26178-72] to VLDL Receptor/VLDL-R - BSA and Azide free
- Suitable for: WB, IHC-P
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
概述
-
产品名称
Anti-VLDL Receptor/VLDL-R抗体[EPR26178-72] (BSA and Azide free)
参阅全部 VLDL Receptor/VLDL-R 一抗 -
描述
兔单克隆抗体[EPR26178-72] to VLDL Receptor/VLDL-R - BSA and Azide free -
宿主
Rabbit -
特异性
This antibody does not cross-react with human LDLR.
-
经测试应用
适用于: WB, IHC-Pmore details
不适用于: Flow Cyt or IP -
种属反应性
与反应: Mouse, Rat, Human -
免疫原
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
阳性对照
- WB: Human and mouse heart tissue lysate treated & untreated with Protein Deglycosylation Mix II; human, mouse and rat liver tissue lysate, human small intestine tissue lysate; 3T3-L1 treated & untreated with1µM Dexamethasone whole cell tissue lysate, THP-1, and Huh7 whole cell lysates; human VLDLR & His-tagged LDLR recombinant protein. IHC-P: Human cardiac muscle and pancreas tissue sections.
-
常规说明
ab302918 is the carrier-free version of ab302917.
ab302917 is unsuitable for mouse and rat IHC
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C. -
存储溶液
pH: 7.20
Constituent: 100% PBS -
无载体
是 -
Concentration information loading...
-
纯度
Protein A purified -
克隆
单克隆 -
克隆编号
EPR26178-72 -
同种型
IgG -
研究领域
相关产品
-
Alternative Versions
-
Compatible Secondaries
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab302918于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
WB |
Use at an assay dependent concentration. Detects a band of approximately 100-150 kDa (predicted molecular weight: 96 kDa).
|
|
IHC-P |
Use at an assay dependent concentration. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
说明 |
---|
WB
Use at an assay dependent concentration. Detects a band of approximately 100-150 kDa (predicted molecular weight: 96 kDa). |
IHC-P
Use at an assay dependent concentration. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
靶标
-
功能
Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation. -
组织特异性
Abundant in heart and skeletal muscle; also ovary and kidney; not in liver. -
疾病相关
Defects in VLDLR are the cause of cerebellar ataxia mental retardation and dysequilibrium syndrome type 1 (CMARQ1) [MIM:224050]; also known as dysequilibrium syndrome (DES) or non-progressive cerebellar disorder with mental retardation. CMARQ1 is a congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation and cerebellar hypoplasia. Additional features include short stature, strabismus, pes planus and, rarely, seizures. -
序列相似性
Contains 3 EGF-like domains.
Contains 8 LDL-receptor class A domains.
Contains 6 LDL-receptor class B repeats. -
翻译后修饰
Ubiquitinated at Lys-839 by MYLIP leading to degradation. -
细胞定位
Membrane. Membrane > clathrin-coated pit. - Information by UniProt
-
数据库链接
- Entrez Gene: 7436 Human
- Entrez Gene: 22359 Mouse
- Entrez Gene: 25696 Rat
- Omim: 192977 Human
- SwissProt: P98155 Human
- SwissProt: P98156 Mouse
- SwissProt: P98166 Rat
- Unigene: 370422 Human
see all -
别名
- FLJ35024 antibody
- Very low density lipoprotein receptor antibody
- Very low-density lipoprotein receptor antibody
see all
图片
-
All lanes : Anti-VLDL Receptor/VLDL-R antibody [EPR26178-72] (ab302917) at 1/1000 dilution
Lane 1 : Human VLDLR recombinant protein 10 ng
Lane 2 : His-tagged human LDLR recombinant protein 10 ng
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 96 kDa
Observed band size: 15-50 kDa why is the actual band size different from the predicted?
Exposure time: 15 secondsThis data was developed using ab302917, the same antibody clone in a different buffer formulation.
Blocking / Diluting buffer and concentration: 5% NFDM/TBST.
This blot was developed using a high sensitivity ECL substrate. The high-sensitivity ECL substrate used allows for the detection of proteins in the mid-femtogram range. -
All lanes : Anti-VLDL Receptor/VLDL-R antibody [EPR26178-72] (ab302917) at 1/1000 dilution
Lane 1 : Untreated 3T3-L1 (mouse embryonic fibroblast), whole cell lysate
Lane 2 : 3T3-L1 treated with1µM Dexamethasone for 48h, whole cell lysate
Lane 3 : THP-1 (human monocytic leukemia monocyte), whole cell lysate
Lane 4 : Huh7 (Human hepatocellular carcinoma epithelial cell), whole cell lysate
Lysates/proteins at 50 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 96 kDa
Observed band size: 100-150 kDa why is the actual band size different from the predicted?This data was developed using ab302917, the same antibody clone in a different buffer formulation.
Blocking / Diluting buffer and concentration: 5% NFDM/TBST
The expression of VLDLR is upregulated in response to Dexamethasone treatment (PMID: 11960750).
Low expression: Huh7 (PMID: 29289645)Exposure time:
Lane 1 and 2: 180 seconds
Lane 3 and 4: 48 seconds -
All lanes : Anti-VLDL Receptor/VLDL-R antibody [EPR26178-72] (ab302917) at 1/1000 dilution
Lane 1 : Untreated human heart tissue lysate at 30 µg
Lane 2 : Human heart tissue lysate treated with Protein Deglycosylation Mix II at 30 µg
Lane 3 : Human liver tissue lysate at 50 µg
Lane 4 : Human small intestine tissue lysate at 50 µg
Lane 5 : Untreated mouse heart tissue lysate at 30 µg
Lane 6 : Mouse heart tissue lysate treated with Protein Deglycosylation Mix II at 30 µg
Lane 7 : Mouse liver tissue lysate at 50 µg
Lane 8 : Rat heart tissue lysate at 50 µg
Lane 9 : Rat liver tissue lysate at 50 µg
Secondary
All lanes : Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/1000 dilution
Predicted band size: 96 kDa
Observed band size: 100-150 kDa why is the actual band size different from the predicted?
Exposure time: 48 secondsThis data was developed using ab302917, the same antibody clone in a different buffer formulation.
Blocking / Diluting buffer and concentration: 5% NFDM/TBST
VLDLR is a glycoprotein of approximately 150 kDa and detected as a 120 kDa band after treated with Protein Deglycosylation MIX II.
Low expression: liver, small intestine (PMID: 7925422; PMID: 11960750; PMID: 29289645) -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VLDL Receptor/VLDL-R antibody [EPR26178-72] (BSA and Azide free) (AB302918)
This data was developed using ab302917, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded human cardiac muscle tissue labeling VLDL Receptor/VLDL-R with ab302917 at 1/500 dilution (0.978 µg/ml) followed by a ready to use Leica DS9800 (BOND™ Polymer Refine Detection). Cytoplasmic staining on cardiac muscle. The section was incubated with ab302917 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Primary diluent was used instead of primary antibody, followed by a ready to use Leica DS9800 (BOND™ Polymer Refine Detection).
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins was used.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VLDL Receptor/VLDL-R antibody [EPR26178-72] (BSA and Azide free) (AB302918)
This data was developed using ab302917, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded human pancreas tissue labeling VLDL Receptor/VLDL-R with ab302917 at 1/500 dilution (0.978 µg/ml) followed by a ready to use Leica DS9800 (BOND™ Polymer Refine Detection). Cytoplasmic staining on islet of human pancreas. The section was incubated with ab302917 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Primary diluent was used instead of primary antibody, followed by a ready to use Leica DS9800 (BOND™ Polymer Refine Detection).
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins was used.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VLDL Receptor/VLDL-R antibody [EPR26178-72] (BSA and Azide free) (AB302918)
This data was developed using ab302917, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded human liver tissue labeling VLDL Receptor/VLDL-R with ab302917 at 1/500 dilution (0.978 µg/ml) followed by a ready to use Leica DS9800 (BOND™ Polymer Refine Detection). Negative control: No staining on human liver was observed. The section was incubated with ab302917 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Primary diluent was used instead of primary antibody, followed by a ready to use Leica DS9800 (BOND™ Polymer Refine Detection).
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins was used.
实验方案
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
数据表及文件
-
Datasheet download
Certificate of Compliance
文献 (0)
ab302918 尚未被引用在任何文献中。